Nvidia bets on agentic AI to turbocharge biotech discovery

At the Bio International Convention, Nvidia's VP for healthcare and life sciences, Kimberly Powell, highlighted how agentic AI can revolutionize biotech discovery. This marks a significant push by the tech giant to integrate advanced AI into the biotech sector, aiming to speed up research and development processes. The emphasis on agentic AI—AI that can act independently and make decisions—underscores a broader trend where AI's capabilities are being leveraged to tackle complex biological challenges, potentially leading to breakthroughs in drug discovery and personalized medicine.